| Cat.No. | Name | Information |
|---|---|---|
| M1743 | X-376 | X-376 is a potent and highly specific ALK small molecule tyrosine kinase inhibitor with IC50 of 0.61 nM. |
| M1873 | LDN-193189 | LDN-193189 is a highly potent small molecule inhibitor of bone morphogenetic protein (BMP) type I receptors ALK2 and ALK3. |
| M1720 | AP26113 (Brigatinib) | AP26113 (Brigatinib) is a highly potent ALK inhibitor with IC50 of 0.6 nM. |
| M2075 | LDK378 | Ceritinib (LDK378) is a highly selective, orally bioavailable ALK inhibitor with IC50 of 0.15 nM. |
| M1794 | SB431542 | SB-431542 is a potent and selective inhibitor of the transforming growth factor-β (TGF-β) type I receptor activin receptor-like kinase ALK5 (IC50 = 94 nM). |
| M1950 | ASP3026 | ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC50 value of 3.5 nM. ASP3026 can inhibit the phosphorylation of IGF-1R, STAT3, AKT and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. |
| M2805 | LDN-193189 dihydrochloride | LDN-193189 dihydrochloride is a selective BMP signaling inhibitor, and inhibits the transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 of 5 nM and 30 nM, respectively, 200-fold selectivity for BMP versus TGF-β. |
| M5320 | Crizotinib hydrochloride | Crizotinib is inhibitor of the c-Met kinase and the NPM-ALK. Crizotinib inhibited cell proliferation in ALK-positive ALCL cells (IC50s=30 nM). Crizotinib is useful in treatment of anaplastic large-cell lymphoma. |
| M2859 | ML347 | ML347 is a selective BMP receptor inhibitor with IC50 of 32 nM for ALK2, >300-fold selectivity over ALK3. Also inhibits ALK1 activity with IC50 of 46 nM. |
| M6168 | Ceritinib (LDK378) dihydrochloride | Ceritinib dihydrochloride (LDK378 dihydrochloride) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. |
| M5613 | Entrectinib | Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. |
| M5309 | ALK-IN-1 | ALK-IN-1 is an analog of AP26113 which is a potent and selective ALK inhibitor. It is also an inhibitor of EGFR. |
| M4984 | CEP-37440 | CEP-37440 is a novel potent and selective Dual FAK/ALK inhibitor with IC50 s of 2.3 nM (FAK) and 120 nM(ALK cellular IC50 in 75% human plasma). |
| M4811 | CH5424802 HCl | CH5424802 HCl is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation. |
| M3975 | Lorlatinib (PF-06463922) | Lorlatinib (PF-06463922) is an oral active, selective, brain osmotic and ATP-competitive ROS1/ALK inhibitor. The Ki of Lorlatinib for ROS1, wild-type ALK and ALK(L1196M) were <0.025 nM, <0.07 nM and 0.7 nM, respectively. Lorlatinib has anticancer activity. |
| M3889 | LDN-214117 | LDN-214117 is a potent and selective ALK2 inhibitor with IC50 of 22 nM and >100 fold selectivity for ALK5. |
| M3781 | NVP-TAE684 | NVP-TAE684 is a highly potent and selective small-molecule ALK inhibitor, which blocked the growth of ALCL-derived and ALK-dependent cell lines with IC(50) values between 2 and 10 nM. |
| M2806 | LDN-212854 | LDN-212854 is a potent and selective BMP receptor inhibitor with IC50 of 1.3 nM for ALK2, about 2-, 66-, 1641-, and 7135-fold selectivity over ALK1, ALK3, ALK4, and ALK5, respectively. |
| M2789 | K02288 | K02288 is a potent, and selective type I BMP receptor inhibitor with IC50 of 1.1, 1.8, 6.4 nM for ALK2, ALK1 and ALK6, showing weaker inhibition on other ALKs (3, 4, 5) and ActRIIA. |
| M2647 | DMH1 | DMH1 is a selective BMP receptor inhibitor with IC50 of 107.9 nM for ALK2, exhibiting no inhibition on AMPK, ALK5, KDR (VEGFR-2) or PDGFR. |
| M2201 | TSR-011 | TSR-011 is a potent, orally available ALK inhibitor. |
| M2186 | UK 383367 | UK 383367 is a potent and selective BMP-1 (procollagen C-proteinase; PCP) inhibitor with IC50 of 44 nM. |
| M2109 | AZD3463 | AZD3463 is a novel ALK/IGF1R inhibitor with IC50 value of 22 nM. |
| M1946 | CEP-28122 | CEP-28122 is a highly potent and selective orally active ALK inhibitor. |
| M1942 | Alectinib | Alectinib (CH5424802) is a highly selective, orally active and potent ALK inhibitor with IC50 of 1.9 nM. Alectinib (CH5424802) also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration. |
| M1932 | GSK1838705A | GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and the insulin receptor with IC50s of 2.0 and 1.6 nmol/L, respectively. |
| M1859 | RepSox | RepSox (ALK5 Inhibitor II) is a potent and ATP-competitive inhibitor of the TGF-β type I receptor ALK5 (IC50 values are 0.004 and 0.023 μM for ALK5 autophosphorylation and ALK5 binding respectively). |
| M57185 | TL13-22 | TL13-22 is a negative control for TL13-12 and a potent ALK inhibitor with an IC50 of 0.54 nM. |
| M57184 | TL13-110 | TL13-110 is a negative control for TL13-112 and a potent ALK inhibitor with an IC50 of 0.34 nM. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
